Actively Recruiting
A Multicenter, Randomized, Single-blind, Active Controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
Led by Huons Co., Ltd. · Updated on 2026-01-13
206
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are conducting a multicenter, randomized, single-blind phase III clinical trial to assess the efficacy and safety of HUC3-637 for patients diagnosed with primary open angle glaucoma or ocular hypertension. This study aims to compare HUC3-637 with an active comparator to better understand its effects on eye pressure related to these conditions. Participants will receive either HUC3-637 or HUC3-637-R, both administered as ophthalmic solutions directly into the eye. These treatments involve topical ocular administration, and the study is designed to actively control and monitor the effects of these drugs on the patients' conditions. During the study, researchers will evaluate the mean change in diurnal intraocular pressure over a 12-week period. Participants will be closely monitored for safety and treatment response throughout the trial duration, which starts in January 2026 and is expected to end in December 2027. The trial includes randomized allocation and single-blind masking to ensure reliable results.
CONDITIONS
Brief Title
Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 19 years and older
- Diagnosed with primary open angle glaucoma or ocular hypertension
- Have fully understood the study and given written informed consent voluntarily
You will not qualify if you...
- Acute or chronic angle-closure glaucoma
- Congenital glaucoma or secondary open-angle glaucoma
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 weeks
Participants receive the study drug, an ophthalmic solution instilled directly into the eye, to evaluate its efficacy and safety for glaucoma or ocular hypertension.
Regular visits during the 12-week treatment period
Trial Site Locations
Total: 1 location
1
Kangbuk Samsung Hospital
Seoul, South Korea
Actively Recruiting
Research Team
R
Rang Lee
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here